多形性胶质母细胞瘤 (GBM) 是最致命的脑癌类型之一，由于其侵袭性且缺乏有效的治疗方案，中位生存期仅为 12 个月。星形细胞瘤和少突胶质细胞瘤被归类为低级别胶质瘤（LGG），有可能进展为继发性 GBM。 YAP1 和 TAZ 是 hippo 通路的转录共激活因子，通过控制细胞增殖和分化在肿瘤发生中发挥重要作用。本研究的目的是分析YAP1和TAZ是否影响星形细胞瘤和少突胶质细胞瘤患者的生存。使用实时PCR对总共22个星形细胞瘤患者样本和11个少突胶质细胞瘤样本进行了分析。我们利用了癌症基因组图谱 (TCGA) 的开放获取数据，重点关注“脑低级神经胶质瘤”。 mRNA 表达率用于验证我们的生存分析结果。YAP1 的表达在星形细胞瘤中是少突胶质细胞瘤中的两倍，而在 TAZ 中没有差异。在少突胶质细胞瘤中，复发肿瘤中TAZ的表达高于原发肿瘤。 YAP1 高表达的星形细胞瘤患者的总生存期明显短于低表达的患者（中位生存期 161 个月 vs. 86 个月，p=0.0248）。这些发现通过 TCGA 数据的生存分析得到了验证。高 YAP1 表达显示与 LGG 较差的总体生存率高度相关。 YAP1 在星形细胞瘤中的表达水平高于少突胶质细胞瘤。版权所有 © 2024 国际抗癌研究所（George J. Delinasios 博士），保留所有权利。

Glioblastoma multiforme (GBM) is one of the most lethal types of brain cancer with a median survival of only 12 months due to its aggressiveness and lack of effective treatment options. Astrocytomas and oligodendrogliomas are classified as low-grade gliomas (LGG) and have the potential to progress into secondary GBM. YAP1 and TAZ are transcriptional co-activators of the hippo pathway and play an important role in tumorigenesis by controlling cell proliferation and differentiation. The aim of this study was to analyze whether YAP1 and TAZ influence the survival in patients with astrocytoma and oligodendroglioma.A total of 22 patient samples of astrocytoma and 11 samples of oligodendroglioma were analyzed using real-time PCR. We utilized open-access data from The Cancer Genome Atlas (TCGA) focusing on "brain lower grade glioma". mRNA expression rates were used to validate our findings on survival analysis.Expression of YAP1 was twice as high in astrocytoma than in oligodendroglioma, whereas there was no difference in TAZ. In oligodendrogliomas, the expression of TAZ was higher in relapsed than in primary tumors. Patients with astrocytoma having a high YAP1 expression had a significantly shorter overall survival than patients with lower expression (median survival 161 vs. 86 months, p=0.0248). These findings were validated with survival analysis of TCGA data.High YAP1 expression shows a high correlation with poorer overall survival in LGG. YAP1 has higher levels of expression in astrocytomas than in oligodendrogliomas.Copyright © 2024 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.